Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial
E J Owen, Z Shoham, B A Mason, H Ostergaard, H S Jacobs, E J Owen, Z Shoham, B A Mason, H Ostergaard, H S Jacobs
Abstract
Objective: To explore the effect of cotreatment with growth hormone (GH) for ovarian stimulation after pituitary suppression.
Design: A randomized, double-blind, placebo-controlled study.
Setting: Specialist Reproductive Endocrine and In Vitro Fertilization (IVF) Unit.
Patients, participants: Twenty-five IVF patients who had responded suboptimally in a previous treatment cycle. A subgroup of 18 patients were found to have ultrasound (US) findings of polycystic ovaries (PCO).
Main outcome measure: The amount of gonadotropin used, development of follicles greater than or equal to 14 mm, number of oocytes collected, fertilized, cleaved and replaced, serum and follicular fluid (FF) insulin-like growth factor I (IGF-I) concentrations.
Results: Cotreatment with GH was associated with a significant reduction in gonadotropins requirement (P less than 0.05). In patients with US-diagnosed PCO more follicles developed (P less than 0.05), more oocytes were collected (P less than 0.03), fertilized (P less than 0.004), and cleaved (P less than 0.02). A significantly higher FF IGF-I concentrations were found in patients receiving cotreatment with GH compared with those who received placebo (P less than 0.04).
Conclusion: We believe that there may be a place for GH treatment in selected IVF cycles after pituitary suppression but what the role of IGF-I should further be investigated.
Source: PubMed